~ In a groundbreaking move, Clario and PathAI have joined forces to offer a streamlined and efficient solution for gastrointestinal (GI) clinical trials. This strategic partnership combines Clario's expertise in endpoint data solutions with PathAI's AI-powered digital pathology services, promising to revolutionize drug development for inflammatory bowel disease (IBD) and other GI disorders.

The collaboration between these two industry leaders offers a single-vendor solution for anatomical pathology services and next-generation video endoscopy analysis. This co-delivery model aims to improve efficiency in global GI studies by streamlining endoscopic and histopathology endpoints. CROs and sponsors will benefit from an end-to-end process that covers training, logistics, tissue processing, slide digitization, image analysis, and data transfers – all under the medical and scientific oversight of experts from both companies. Additionally, investigational sites will experience simplified workflows with improved training, reporting, and document management.

Dr. Marcela Vieira, Clario's Medical Director of Gastroenterology, expressed her excitement about the partnership: "At Clario, we have always been at the forefront of supporting GI clinical trials. We are thrilled to combine our strengths with PathAI's capabilities in the area of discovery and patient care. The integration of endoscopy and histopathology has the potential to unlock new avenues for clinical research, and we are proud to be leading this effort with our partners at PathAI."

More on Boston Chron

• Dr. Jay A. Johannigman Delivers Lecture at the John R. Border Memorial Lectureship in Buffalo
• Powering the Next Frontier of the $1 Trillion Space Economy: Ascent Solar Technologies (N A S D A Q: ASTI)
• Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
• Travel Industry Leaders Gather in Antigua for the 2025 Travel Agency Owners Forum
• Orton-Gillingham Approach for Students with Dyslexia

Clario has a proven track record in supporting over 130 GI studies through advanced imaging solutions such as endoscopy, MRI, and ultrasound. Their team of scientists and cutting-edge technologies help reduce site burden and enhance trial efficiency with AI-supported reading for ulcerative colitis (UC) as well as HD-video endoscopy support.

PathAI brings its expert GI pathologist network and state-of-the-art anatomical pathology services to the partnership while optimizing specimen handling and histological assessments. Their AI-powered tools enhance UC assessment, minimize variability in histological scoring, and expedite biomarker discovery.

Matt Grow, Chief Business Officer & President of Biopharma at PathAI, shared his enthusiasm for the collaboration: "We are thrilled to partner with Clario to provide a cutting-edge solution for IBD clinical trials. Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery, and therapy development in IBD."

This strategic partnership between Clario and PathAI is set to revolutionize the way GI clinical trials are conducted. With their combined expertise and advanced solutions, they aim to improve diagnostic accuracy, boost efficiency, and enable reliable turnaround times – ultimately leading to better treatments for patients with GI disorders.

---

Show All News | Report Violation